Xconomy
SEPTEMBER 27, 2016
San Diego’s Avalon Ventures led the Series A round, and has established Fortis at COI Pharma, the firm’s biotech incubator (which now houses 16 life sciences startups). Lilly Asia Ventures, Osage University Partners, and Vivo Capital joined in the deal, according to a statement from Avalon. Bregua Corp.,
socalTECH
JANUARY 18, 2011
and FAIL Blog web sites, apparently was spawned out of an introduction at last year's Twiistup technology conference, according to investor the Foundry Group. Along with Foundry, both Madrona Ventures and San Diego's Avalon Ventures were investors in the round. READ MORE>>.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Xconomy
AUGUST 17, 2016
and San Diego’s Avalon Ventures. Stengone said the new funding also will help the company evaluate the use of AVB-620 in other types of cancer surgery, to advance new cancer drugs that rely on Avelas’ proprietary technology, and to expand the company’s current roster of “seven employees and an army of consultants.”.
Xconomy
AUGUST 31, 2016
In 2009, Tsien and Kevin Kinsella of Avalon Ventures founded San Diego’s Avelas Biosciences to develop fluorescent proteins that change color in the presence of cancer cells. In the statement released by UC San Diego, chancellor Pradeep Khosla said, every honor Tsien received was “justly deserved, and always received with humility.”.
Xconomy
JULY 10, 2016
It was during this time, she recalled, when Bock met Kevin Kinsella of San Diego’s Avalon Ventures. In 1998, Nelsen recalled, “People thought we were crazy” to apply optics to genotyping when Affymetrix and its solid phase arrays represented the dominant technology at the time. They had a lot of fun.”.
Xconomy
JULY 19, 2016
Existing investors Avalon Ventures and Correlation Ventures joined in the round. The company’s technology is based on research led by Floyd Romesberg, a biological chemist at The Scripps Research Institute. The San Diego firms have invested $6 million since 2014, when Synthorx was founded , CEO Court Turner said yesterday.
Xconomy
DECEMBER 7, 2018
Synthorx, which is working to develop cancer and autoimmune therapies using technology that allows it to expand the genetic alphabet, raised $131 million in an upsized IPO on Thursday. The company sold more than 11.9 million shares at $11 apiece. million additional shares are available for its underwriters to purchase.
Expert insights. Personalized for you.
40 
Let's personalize your content